I was almost three years ago to the day (May 22) that Obagi Medical Products (Nasdaq:OMPI) was trading around $8. Over the next three years to May 5, 2011, it was up about 62% to $13, compared to 10% for the iShares Russell Microcap Index ETF (NYSE:IWC). Then uncertainty struck. After the markets closed May 5, 2011, Obagi announced a first quarter loss of 13 cents a share due to two situations that I'll explain shortly. The next day its stock dropped 24%, erasing over half its gains since I wrote good things about the company back in 2008. It's not very often that stocks go on sale, but Obagi's current pitfalls present real opportunity for investors. I'll explain why.
TUTORIAL: Fundamental Analysis: Qualitative Factors - The Industry
The first issue involves an ongoing lawsuit between Dr. Zein Obagi, founder of Obagi, and the company. Originally filed in January 2010 in the California courts by Dr. Obagi, the lawsuit made certain claims based on the doctor's 2006 separation-agreement. The parties were unable to reach an agreement until May 2 of this year. As part of this agreement, Obagi Medical Products agreed to pay the doctor a one-time payment of $5 million. In addition, it incurred $2.2 million in litigation costs from the lawsuit . Both were included in the first quarter SG&A expenses and the company expects to have $600,000 more fees during the second quarter. Its general liability insurance carrier has agreed to cover some of the $7.2 million, although it's unknown just how much. At this time, it's safe to assume less than more. Nonetheless, the issue is put to bed and no longer a distraction for management. (Learn more in Cover Your Company With Liability Insurance.)
The second issue involves the Texas Department of State Health Services. In November 2009, the company received a letter from the state agency suggesting that products containing 4% hydroquinone, which it was selling in Texas, were unapproved new drugs. The two parties went back and forth until April of this year when the Texas Attorney General's office said it was in violation of state law and impounded its product. The company is voluntarily stopping selling its products in Texas and is accepting returns from customers for a full refund. As a result, $1.9 million for sales returns and allowances were added to "accrued liabilities" on the balance sheet, overall revenues were reduced by an equivalent amount and gross profits were reduced by $1.6 million. In 2010, Texas accounted for 8.8% of overall revenues so an ongoing battle will cost the company money in terms of lost revenue, potential penalties and litigation fees. This situation isn't over by a long shot.
Obagi Medical Products and Peers
|Company||EV/EBITDA - Next 12 Months|
|Obagi Medical Products (Nasdaq:OMPI)||7.67|
|Johnson & Johnson (NYSE:JNJ)||8.08|
|Roche Holding (OTCC:RHHBY)||8.16|
|Medicis Pharmaceutical (NYSE:MRX)||5.74|
What It Means
In its Q1 earnings release, Obagi management lays out a non-GAAP income statement that adds back the $1.9 million in lost revenue, $1.6 million in lost gross profits and $7.2 million in litigation settlement costs. An apples-to-apples comparison sees it delivering 16 cents in earnings per share in the first quarter of 2011 compared to 11 cents a year earlier. That's a 45% increase so the fundamental business is still very profitable. The real question for investors is the revenue outlook. Due to the Texas situation, its revised guidance in 2011 is $114 to $116 million, which is flat to last year. This means it expects the rest of its business to deliver approximately 8.8% revenue growth in 2011 and that's the worrisome part. Since passing the $100-million mark in sales back in 2007, if it meets guidance, it will have added just $11 million or so in revenue over a four-year period. That won't cut it. Nonetheless, its earnings per share in 2011 should be its best on record at 75 cents, a 70% increase over 2010. With the $3 haircut it got May 5, we are talking about a forward P/E of 13 for a company that up until these two pitfalls; was going to come close to doubling its EPS for the year. (Explore the controversies surrounding companies commenting on their forward-looking expectations, check out Can Earnings Guidance Accurately Predict The Future?)
The more I write about stocks, the more I realize that the most successful investors are those who are jumping into the pool when the rest of us are jumping out. So, while many investors are looking for the fastest way out, it may be a fine time for you to cannonball into some OMPI's stock.
Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!
Stock AnalysisStuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
EconomicsEmerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
Stock AnalysisPepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
InvestingHow do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
Investing BasicsIs there an opportunity in exotic currencies right now, or are you safer sticking to the major ones?
Mutual Funds & ETFsCompare and contrast the rise of America's big three institutional asset managers: BlackRock Funds, The Vanguard Group and State Street Global Advisors.
Stock AnalysisThese three stocks are resilient, fundamentally sound and also pay generous dividends.
ProfessionalsMutual funds are a good choice for emotional investors. Here are five popular funds to consider.
Investing NewsAre stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
Investing NewsHere are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
Mutual funds can invest in initial public offerings (IPOS). However, most mutual funds have bylaws that prevent them from ... Read Full Answer >>
When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
The rise of index trading may increase the overall vulnerability of the stock market due to increased correlations between ... Read Full Answer >>
If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>